1. Tempero MA. Incremental successes lead to improved patient care. Accessed January 23, 2013.

Continue Reading

2. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012. Accessed January 23, 2013.

3. Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). Accessed January 23, 2013.

4. NCT00844649. Phase III study of ABI-007 (albumin-bound paclitaxel) plus gemcitabine versus gemcitabine in metastatic adenocarcinoma of the pancreas. Accessed January 23, 2013.

5. “Nab-Paclitaxel Plus Gemcitabine New Standard of Care for First-Line Metastatic Pancreatic Cancer.” Accessed January 23, 2013.

6. Aufforth RD, Baker JJ, Witek MA, et al. Circulating tumor cells as a possible marker for micrometastatic disease in patients with localized pancreatic cancer. Accessed January 24, 2013.

7. Zubritsky L, Alkhateeb A, Leitzel K, et al. Pretreatment serum ferritin and overall survival in metastatic pancreatic cancer. Accessed January 28, 2013.

8. Sangar V, Ricigliano M, O’Reilly EM, et al. Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance. Accessed January 24, 2013.

9. Tzung-Kai Chen K, Singla S, Papavasiliou P, Arrangoiz R, Gaughan JP, Hoffman JP. Patterns of recurrence and outcomes in pancreatic cancer. Accessed January 25, 2013.

10. Deplanque G, Demarchi M, Hebbar M, et al. Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial. Accessed January 28, 2013.

11. NCT00789633. A phase 3 study to compare efficacy and safety of masitinib in combination with gemcitabine, to placebo in combination with gemcitabine, in treatment of patients with advanced/metastatic pancreatic cancer. Accessed January 28, 2013.

12. Infante JR, Somer, BG, Park, JO, et al. A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Accessed January 28, 2013.

13. NCT01231581. Study of GSK1120212 plus gemcitabine vs placebo plus gemcitabine in metastatic pancreatic cancer. Accessed January 28, 2013.